Daiki Ousaka

Dr. Daiki Ousaka

Okayama University, Okayama, Japan
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KHKenta Hirai
Kenta Hirai
Daiki OusakaDaiki Ousaka
Daiki Ousaka
YFYosuke Fukushima
Yosuke Fukushima
MKMaiko Kondo
Maiko Kondo
TETakahiro Eitoku
Takahiro Eitoku
HOHidemasa Oh
Hidemasa Oh
Cardiosphere-derived exosomes improve cardiac function in dilated cardiomyopathy and provide safety lead-in results for further clinical translation.

1 October 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
KNKentaro Nakata
Kentaro Nakata
MOMikio Okazaki
Mikio Okazaki
DSDai Shimizu
Dai Shimizu
KSKen Suzawa
Ken Suzawa
KSKazuhiko Shien
Kazuhiko Shien
STShinichi Toyooka
Shinichi Toyooka
During ischemia reperfusion (IR) injury, high mobility group box 1 (HMGB1), a chromatin binding protein, is released from necrotic cells and triggers inflammatory responses. We assessed the therapeutic effect of a neutralizing anti-HMGB1 monoclonal antibody (mAb) on lung IR injury. A murine hilar clamp model of IR was used, where mice were divided into sham and IR groups with intravenous administration of anti-HMGB 1 mAb or control mAb. We analyzed the effect of anti-HMGB1 mAb against IR injury by assessing lung oxygenation, lung injury score, neutrophil infiltration, expression of proinflammatory cytokines and chemokines, levels of mitogen-activated protein kinase (MAPK) signaling, and measurement of apoptotic cells. Anti-HMGB1 mAb significantly decreased the plasma level of HMGB1 elevated by IR. The severity of IR injury represented by oxygenation capacity, lung injury score, and neutrophil infiltration was significantly improved by anti-HMGB1 mAb treatment. The expression of proinflammatory factors, including IL-1 beta, IL-6, IL-12, TNF-alpha, CXCL-1, and CXCL-2, and phosphorylation of p38 MAPK were both significantly reduced by anti-HMGB1 mAb treatment. Furthermore, anti-HMGB1 mAb treatment suppressed apoptosis, as determined through TUNEL assays. Overall, anti-HMGB1 mAb ameliorated lung IR injury by reducing inflammatory responses and apoptosis. Our findings indicate that anti-HMGB1 mAb has potential for use as a therapeutic to improve IR injury symptoms during lung transplantation. (C) 2021 Published by Elsevier Inc.

Verified
Journal Article
Open access
PDF file
YFYasuhiro Fujii
Yasuhiro Fujii
Tatsuyuki NakataniTatsuyuki Nakatani
Tatsuyuki Nakatani
Daiki OusakaDaiki Ousaka
Daiki Ousaka
SOSusumu Oozawa
Susumu Oozawa
YSYasushi Sasai
Yasushi Sasai
SKShingo Kasahara
Shingo Kasahara
The medical device market is a high-growth sector expected to sustain an annual growth rate of over 5%, even in developed countries. Daily, numerous patients have medical devices implanted or inserted within their bodies. While medical devices have significantly improved patient outcomes, as foreign objects, their wider use can lead to an increase in device-related infections, thereby imposing a burden on healthcare systems. Multiple materials with significant societal impact have evolved over time: the 19th century was the age of iron, the 20th century was dominated by silicon, and the 21st century is often referred to as the era of carbon. In particular, the development of nanocarbon materials and their potential applications in medicine are being explored, although the scope of these applications remains limited. Technological innovations in carbon materials are remarkable, and their application in medicine is expected to advance greatly. For example, diamond-like carbon (DLC) has garnered considerable attention for the development of antimicrobial surfaces. Both DLC itself and its derivatives have been reported to exhibit anti-microbial properties. This review discusses the current state of DLC-based antimicrobial surface development.

1 May 2017 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
Daiki OusakaDaiki Ousaka
Daiki Ousaka
YFYasuhiro Fujii
Yasuhiro Fujii
SOSusumu Oozawa
Susumu Oozawa
MNMasahiro Nishibori
Masahiro Nishibori
YKYosuke Kuroko
Yosuke Kuroko
SSShunji Sano
Shunji Sano

23 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
DWDengli Wang
Dengli Wang
Daiki OusakaDaiki Ousaka
Daiki Ousaka
HQHandong Qiao
Handong Qiao
ZWZiyi Wang
Ziyi Wang
KZKun Zhao
Kun Zhao
MNMasahiro Nishibori
Masahiro Nishibori
Intracerebral hemorrhage (ICH) is recognized as a severe clinical problem lacking effective treatment. High mobility group box-1 (HMGB1) exhibits inflammatory cytokine-like activity once released into the extracellular space from the nuclei. We previously demonstrated that intravenous injection of rat anti-HMGB1 monoclonal antibody (mAb) remarkably ameliorated brain injury in a rat ICH model. Therefore, we developed a humanized anti-HMGB1 mAb (OKY001) for clinical use. The present study examined whether and how the humanized anti-HMGB1 mAb ameliorates ICH injury in common marmosets. The results show that administration of humanized anti-HMGB1 mAb inhibited HMGB1 release from the brain into plasma, in association with a decrease of 4-hydroxynonenal (4-HNE) accumulation and a decrease in cerebral iron deposition. In addition, humanized anti-HMGB1 mAb treatment resulted in a reduction in brain injury volume at 12 d after ICH induction. Our in vitro experiment showed that recombinant HMGB1 inhibited hemoglobin uptake by macrophages through CD163 in the presence of haptoglobin, suggesting that the release of excess HMGB1 from the brain may induce a delay in hemoglobin scavenging, thereby allowing the toxic effects of hemoglobin, heme, and Fe2+ to persist. Finally, humanized anti-HMGB1 mAb reduced body weight loss and improved behavioral performance after ICH. Taken together, these results suggest that intravenous injection of humanized anti-HMGB1 mAb has potential as a novel therapeutic strategy for ICH.

Verified
Journal Article
Open access
PDF file
GMGenya Muraoka
Genya Muraoka
YFYasuhiro Fujii
Yasuhiro Fujii
KLKeyue Liu
Keyue Liu
HQHandong Qiao
Handong Qiao
DWDengli Wang
Dengli Wang
MNMasahiro Nishibori
Masahiro Nishibori
Spinal cord ischemia–reperfusion (SCI/R) injury remains a major clinical challenge with limited therapeutic options. High-mobility group box 1 (HMGB1), a proinflammatory mediator released during cellular stress, has been implicated in the pathogenesis of ischemia–reperfusion-induced neural damage. In this study, we investigated the neuroprotective potential of the anti-HMGB1 monoclonal antibody (mAb) in a rabbit model of SCI/R injury. Male New Zealand White rabbits were anesthetized and subjected to 11 min of abdominal aortic occlusion using a micro-bulldog clamp following heparinization. Anti-HMGB1 mAb or control IgG was administered intravenously immediately after reperfusion and again at 6 h post-reperfusion. Neurological function was assessed at 6, 24, and 48 h after reperfusion using the modified Tarlov scoring system. The rabbits were euthanized 48 h after reperfusion for spinal cord and blood sampling. Treatment with anti-HMGB1 mAb significantly improved neurological outcomes, reduced the extent of spinal cord infarction, preserved motor neuron viability, and decreased the presence of activated microglia and infiltrating neutrophils. Furthermore, it attenuated apoptosis, oxidative stress, and inflammatory responses in the spinal cord, and helped maintain the integrity of the blood–spinal cord barrier. These findings suggest that anti-HMGB1 mAb may serve as a promising therapeutic agent for SCI/R injury.